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Abstract: Corneal ectasia, a weakening of corneal integrity, occurs both due to acquired and 
congenital conditions such as keratoconus. It is a progressing condition that affects both visual 
acuity, and corneal stability. Various methods exist for correcting this impairment, however 
none address the inherit pathology, an increase laxity of the corneal stroma. Collagen cross-
linking, a new, minimally invasive method, aims to strengthen the stroma by inducing cross 
links between neighboring collagen ﬁ  bers. This method results in an increase in corneal tensile 
strength, with no medium term adverse effects on its normal architecture. Clinically, treated 
patients display improvement in both visual acuity and keratometric readings. This method may 
provide clinicians with easily accessible tools to stop the progression, and even correct visual 
deterioration due to corneal ectasia. Here we review the current information regarding this new 
method, as well as discuss its potential beneﬁ  ts and downfalls.
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Introduction
The cornea, the anterior structure of the eye, is a convex transparent barrier. It serves 
to maintain the intact structure of the eye and focus a clear and minimally deviated 
penetration of light onto the retina. It consists of ﬁ  ve anatomically separate layers: 
epithelium; Bowmen’s layer; stroma; Descement’s membrane; and endothelium. The 
stroma accounts for 90% of the corneal thickness. It is composed mainly of type 1 
collagen ﬁ  brils with types III, V, and VI also found. These are woven into equidistant 
lamellae, interspersed with keratocytes. These are charged with stromal maintenance 
and wound healing (Watsky et al 2005).
Corneal ectasia represents a group of disorders characterized by inherent corneal 
weakness and instability leading to protrusion, astigmatism, loss of visual acuity, and 
potentially even perforation (Krachmer et al 1984). This entity comprises of both 
primary and secondary or iatrogenic conditions, all leading to similar manifestations 
of loss of corneal stability. Of the congenital disorders, keratoconus represents 
the primary cause, affecting up to one in 2000 people (Rabinowitz 1998). This 
congenital, noninﬂ  ammatory, usually bilateral disease manifests as a progressing 
stromal instability, leading to a reduction in corneal rigidity (Andreassen et al 1980) 
and may affect visual acuity to such an extent as to require penetrating keratoplasy in 
up to 20% of patients (Pramanik et al 2006). Treatment options include conservative 
approaches, aimed at maintaining visual acuity, such as rigid contact lenses placed to 
straighten corneal aberrations (Garcia-Lledo et al 2006). Alternatively, more invasive 
methods are applied using intrastromal corneal implants (Ertan and Colin 2007), 
performing anterior lamellar keratoplasty, and penetrating keratoplasty in extreme 
cases (Pramanik et al 2006; Tan and Por 2007). However, these therapies only address 
the refractive consequences of the disease and not the underlying pathology, namely 
a stromal instability stemming from collagen abnormalities (Rabinowitz 1998), and Clinical Ophthalmology 2008:2(4) 864
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with the exception of corneal transplantation do not halt the 
progression of the disease.
Collagen cross-linking is a new approach that directly 
targets these stromal imbalances. By using ultraviolet (UV) 
irradiation and a photomediator, new covalent cross links are 
induced between collagen ﬁ  brils and corneal rigidity improved 
(Wollensak 2006). Cross-linking is a well established method 
used in polymer industries for the stabilization of tissues. 
Chemical cross-linking with glutaraldehyde is used in the 
preparation of prosthetic heart valves (Jayakrishnan and 
Jameela 1996), papraformaldehyde is used for tissue hardening 
in pathology (Melan 1994) and UV cross-linking is used to 
harden dentistry ﬁ  llings (de Gee et al 1998). Furthermore, studies 
have shown that keratoconus is an uncommon phenomenon 
among diabetic patients, as well as progression of the disease 
at an older age. This possibly reﬂ  ects collagen cross-linking 
induced by advanced glycation endproducts (Bailey et al 
1995; Seiler et al 2000; Krueger and Ramos-Esteban 2007), 
or following age-related cross-linking (Reiser 1991; Malik 
et al 1992; Elsheikh et al 2007).
Method
Inducing cross links between neighboring collagen ﬁ  bers 
is achieved by combining the photosensitizer riboﬂ  avin 
with an initiating UVA beam. Exposing riboﬂ  avin to UVA 
light promotes its photomediator properties and extends 
the effects of the irradiation to the surrounding tissue. 
Following exposure, riboflavin is excited into a triplet 
state thereby generating reactive oxygen species; singlet 
oxygen and superoxide anions. These then act to induce 
the formation of new covalent bonds between the amino 
acids of neighboring collagen ﬁ  bers (Seiler et al 2000). The 
wavelength of 370 nm is used to achieve maximal absorption 
by the riboﬂ  avin, while remaining below harmful DNA and 
retinal radiation levels (Spoerl et al 2007).
The treatment is conducted following local anesthesia of 
the eye. An abrasion of a central corneal circle is created by 
mechanical removal of the epithelium for better riboﬂ  avin 
diffusion into the stroma. This is made at a size of between 
5–9 mm according to the desired treatment area (Caporossi 
et al 2006; Hafezi et al 2007; Kanellopoulos and Binder 
2007). A 0.1% riboﬂ  avin solution in 20% dextran is applied 
manually every 2–5 minutes, starting 5 minutes before UVA 
exposure to allow stromal saturatuion. The irradiation is per-
formed from a distance of 1 cm for 30 minutes. A UVA diode 
at a wave length of 365–370 nm is used to deliver an irradi-
ance of 3 mW/cm2 (a total dose of 5.4 J/cm2 of the cornea) 
(Wollensak et al 2003a; Seiler and Hafezi 2006). Repeated 
applications of riboﬂ  avin and topical anesthesia to the cornea 
are performed every 5 minutes. Corneal temperature during 
the procedure is constant and does not cause thermal damage 
(Mencucci et al 2007). It should be noted that alternative 
protocols have been reported using irradiances distances of 
up to 10 cm (Hafezi et al 2007; Mazzotta et al 2007b), ribo-
ﬂ  avin application up to 30 minutes before irradiation (Hafezi 
et al 2007; Spoerl et al 2007) and repeated applications of 
physiological salt solutions to maintain corneal moisture 
(Hafezi et al 2007; Kymionis et al 2007b). Following the 
treatment a contact lens is ﬁ  tted until re-epitalization and 
local antibiotics and steroids are applied for a duration of up 
to several weeks (Wollensak et al 2003a; Hafezi et al 2007; 
Spoerl et al 2007).
Discussion
The efﬁ  cacy and safety of this new, minimally invasive 
method for correcting corneal ectasia has been the focus of 
recent studies. Most work has focused around keratoconus 
patients, while more recent reports have been published on 
iatrogenic corneal ectasia as following laser-assisted in situ 
keratomileusis (LASIK) (Hafezi et al 2007; Kohlhaas et al 
2005).
To examine the change in corneal rigidity stress-strain 
tests were conducted on porcine corneas. These tests showed 
that collagen cross-linking by glutaraldehyde, Karnovsky’s 
solution, or riboﬂ  avin-UV irradiation increased the rigidity 
of the treated corneas compared with controls (Spoerl et al 
1998; Spoerl and Seiler 1999). The treated porcine corneas 
showed an average increase in rigidity of 71.9%, while stiff-
ness of treated human corneas increased by a mean of 328.9% 
(Wollensak et al 2003b).
Although the treatment increased the mechanical strain of 
the cornea, its effect was not uniform through its entire depth. 
Stress-strain tests conducted on anterior and posterior corneal 
ﬂ  aps showed a signiﬁ  cant increase in corneal stiffness in the 
anterior 200 μm compared with the posterior 200 μm. The 
stiffness of the posterior treated sections showed no differ-
ence from that of untreated controls (Kohlhaas et al 2006). 
Furthermore, histological sections of treated corneas revealed 
that the treatment effected the cornea up to a depth of 300 μm, 
creating a clinically visible demarcation line separating the 
anterior cross-linked stroma and the posterior unaffected 
cornea (Seiler and Hafezi 2006). This suggests that the UVA 
irradiation is lost across the cornea and does not penetrate its 
full depth, possibly due to a shielding effect of the photosen-
sitizer riboﬂ  avin that absorbs up to 95% of the UVA radiation 
at the endothelium level (Spoerl et al 2007). Thus, a constant Clinical Ophthalmology 2008:2(4) 865
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depth of effect is achieved with no disturbance to underlying 
structures including the endothelium. This may also explain 
the difference in increased rigidity observed between human 
and porcine corneas. Whereas in human corneas over 50% of 
the corneal thickness was effected (central corneal thickness 
was measured as 550 ± 40 μm), under 40% of the porcine 
corneas was treated (central corneal thickness of 850 ± 70 μm) 
(Wollensak et al 2003b). Such cross-linked corneas also 
displayed increased resistance to collagen enzymatic inges-
tion (Spoerl et al 2004b) and thermal shrinkage (Spoerl et al 
2004a), further indicating an increased stiffness.
To explore the cellular effects of this treatment, histo-
logical sections were obtained from both treated animal and 
human corneas. Measurements of anterior section collagen 
diameter of treated rabbit corneas showed an increase of 
12.2% compared to controls. This was also signiﬁ  cantly 
greater than an increase of 4.6%, noted in posterior sections 
(Wollensak et al 2004). Such increased diameter may reﬂ  ect a 
molecular spacing of the collagen, brought on by the oxidative 
induced links between ﬁ  bers (Tanaka et al 1988). Histological 
evaluation further revealed a delayed process of keratocyte 
apoptosis, peaking at 24 hours following treatment. The 
extent and depth of cell death were dose-dependent, reaching 
300 μm at the clinically used surface irradiance of 3 mW/cm2 
(Wollensak et al 2004), and correlating to the affected zone 
according to the tensile studies. Such delayed type apoptosis 
was observed at all treated levels, even at the endothelial 
cell layer when treatment was directed at rabbit corneas 
under 400 μm thickness (Wollensak et al 2003b). Serial 
histological follow-up of treated rabbit corneas revealed 
that following such extensive apoptosis, a regeneration 
process is initiated, leading by 4–6 weeks to a repopulation 
of both stromal keratocyes and spacing out of endothelial 
cells (Wollensak et al 2007). Confocal microscopy studies 
conducted on corneas of human keratoconus patients showed 
a depletion of keratocytes in the treated zone up to a depth 
of 350 μm, not affecting the endothelium (Mazzotta et al 
2007b). The numbers of keratocytes decreased during the 
ﬁ  rst 2–3 months following treatment, when a repopulation 
by activated keratocytes took place, peaking at 6 months. In 
these patients, keratocyte depletion was accompanied by an 
increased corneal edema, which resolved with keratocyte 
repopulation.
Thus, these studies show that while collagen cross-linking 
induces cellular apoptosis in all treated layers, later regen-
eration processes result in repopulation and normal tissue 
histology. However, it should be noted that as endothelial 
cells do not regenerate, any damage to the endothelium 
is irreversible. In cases when the endothelium is affected, 
as is the concern in patients with corneas under 400 μm 
(Wollensak et al 2003b), the long term consequences of 
such irreversible damage remain unknown. As the treatment 
affects a known and constant range, damage to such deeper 
structures may be averted by maintaining a minimal corneal 
thickness before treatment.
To date, few studies have examined the effectiveness of 
collagen cross-linking in treating keratoconus and improving 
visual acuity. In a prospective study, Wollensak and 
colleagues (2003a, 2003c) performed collagen cross-linking 
on 22 moderate to severe keratoconus patients. Follow-up 
was for up to 4 years (3–47 months) and included visual 
acuity, corneal topography and endothelial cell counts. In 
20 patients refractive follow-up was performed. In 19 patients, 
K readings did not progress and in 65% of cases an average 
regression of 2.0 diopters was noted. Best corrected visual 
acuity (BCVA) improved in 65% of cases by an average of 
1.26 lines and the spherical equivalent refractive error by an 
average of 1.14 diopters. No signiﬁ  cant change in endothelial 
cell density or other adverse reactions were noted. Although 
follow-up time among the different patients varied, this 
work was the ﬁ  rst to show a signiﬁ  cant improvement in 
the outcome of moderate and severe keratoconus patients 
following collagen cross-linking treatment. In a second study 
10 patients were followed for 6 months after the procedure. 
In these cases BCVA improved by an average of 1.66 lines 
with a mean K readings reduction of 2.1 diopters. As in 
the former study, no changes were noted in endothelial 
cell counts or intraocular pressure (Caporossi et al 2006). 
These ﬁ  rst clinical studies provide evidence regarding the 
medium term beneﬁ  t of this procedure and also indicate that 
no other corneal effects take place. Recently a case report 
has been published of a keratoconus patient, with a BCVA 
of 20/40, who underwent CCL in one eye (Kanellopoulos 
and Binder 2007). Twelve months later topography-guided 
photorefractive keratectomy (PRK) was performed on the 
same eye. He was followed for another 18 months and his 
ﬁ  nal BCVA was 20/15, with no change to endothelial cell 
counts. Meanwhile, BCVA of his untreated eye regressed 
from 20/15 to 20/25.
Recent reports suggest this method may have potential 
uses also in non keratoconus corneal ectasia (Kohlhaas et al 
2005). Hafezi and colleagues (2007) reported a series of 
10 patients treated with collagen cross-linking following 
LASIK-induced keratectasia. Patients were followed for up 
to 25 months post-treatment. In all cases the progression of 
corneal ectasia was halted with an improvement in 5 patients Clinical Ophthalmology 2008:2(4) 866
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of over 2 diopters in K readings. Furthermore, in 4 cases 
BCVA improved by more than 2 lines.
Though collagen cross-linking is a minimally invasive 
method, recent reports have indicated possible adverse 
effects. Mazzotta and colleagues (2007a) have presented 
two cases of postoperative corneal haze among a cohort of 
40 eyes of 39 keratoconus patients. Preoperative BCVA and 
keratometric readings as well as in vivo confocal examinations 
were performed on all patients. They report confocal ﬁ  ndings 
which possibly reﬂ  ect keratoconus. In two cases unchanging 
stromal haze appeared 2–3 months following the procedure 
and was resistant to topical steroid treatment. Repeated 
examination of the preoperative confocal studies of these 
patients revealed a reticular pattern of stromal microstriae that 
may imply advanced keratoconus. BCVA in these patients 
improved despite the haze. Although these confocal ﬁ  ndings 
are not unequivocally due to keratoconus, the authors suggest 
them to be a relative contra-indication to performing the 
procedure. Additional case reports describe diffuse lamellar 
keratitis (Kymionis et al 2007a) and a reactivation of herpetic 
keratitis (Kymionis et al 2007b) following collagen cross-
linking. In both cases prompt diagnosis and treatment resulted 
in a favorable resolution.
When judging the use of a treatment with the potential 
of causing damage to ocular structures one must consider 
its safety and possible harmful consequences. UV radiation 
is known to be harmful to the endothelium, lens, and retina 
(Pitts et al 1977; Glickman 2002). Using a wavelength of 
360–370 nm with an accumulated irradiance of 5.4 J/cm2 
ensures that the exposure of all these structures is below 
harmful levels (Spoerl et al 2007). However, the occurrence 
of a nonhomogenous irradiation ﬁ  eld may create localized 
hot spots of increased radiance with potential harmful 
consequences. Therefore, for clinical use, a uniformly emit-
ting irradiance source is needed and must be continuously 
evaluated. Further protection is achieved by the presence of 
riboﬂ  avin in the cornea, which was shown to reach up to 400 μm 
after 30 minutes of application. This then provides an UV 
absorption coefﬁ  cient that shields the more posterior struc-
tures including the endothelium (Spoerl et al 2007). When 
treatment was conducted on corneas of less than 400 μm, 
apoptotic damage was noted in the endothelium (Wollensak 
et al 2003b). This issue may be of greater concern when 
treating patients following LASIK when the post-treatment 
effective corneal thickness may very well be under 400 μm 
(Hafezi et al 2007). While the shielding effect and distance 
from the treated area ensure the lens and retina are exposed to 
radiation well below harmful levels, the endothelium is still 
exposed to radiance which is lower than harmful levels only 
by a factor of 2 (0.32 J/cm2) (Spoerl et al 2007). Thus, any 
variance in the irradiation ﬁ  eld or corneal thickness may lead 
to direct damage to this layer. To ensure that the conducted 
procedure is safe to all ocular structures it is paramount to 
maintain a homogenous irradiation ﬁ  eld at a wavelength and 
irradiance below harmful levels, good stromal penetration of 
riboﬂ  avin and adequate corneal thickness. For a more detailed 
review of the safety considerations of collagen cross-linking 
see Spoerl and colleagues (2007).
Our personal experience with collagen cross-linking 
includes 70 patients treated during the past 2 years. Most 
patients suffered from keratoconus (n = 68), 12 treated 
following the insertion of intra-stromal corneal rings. The 
remaining patients (n = 2) were treated for corneal ectasia 
following LASIK surgery. Our overall impression in these 
cases is of an improvement in K readings and BCVA, with 
no adverse events noted to date.
Conclusions
Keratoconus, and other corneal ectasias, present us with a 
treatment challenge in the hope of halting their progression 
and possibly correcting any refractive and stability deterio-
ration. Studies in both animal models and human patients 
indicate that collagen cross-linking results in an increase in 
corneal stiffness and improvement of visual acuity. Further-
more, although the method affects the cellular composition 
of irradiated structures no lasting effect is generally noted 
in corneal architecture. Collagen cross-linking provides 
us for the ﬁ  rst time with a minimally invasive approach 
to addressing the underlying pathology in corneal ectasia, 
halting its progression, and possibly even improving visual 
acuity. While it may halt progression of corneal ectasia, 
collagen cross-linking does not in itself affect corneal cur-
vature, and thus may require the use of other means, such 
as intrastromal corneal rings (Ertan and Colin 2007) or rigid 
contact lenses (Garcia-Lledo et al 2006) to correct refractive 
errors (Tan and Por 2007). Though this method appears to 
offer an improvement to patients suffering from corneal 
ectasia, it must be noted that its safety and long-term effects 
have not been extensively studied. The turnover rate of col-
lagen ﬁ  bers in the cornea is several years (Ihanamaki et al 
2001) and it remains unclear whether the changes noted in 
corneal stability will last or whether its effects are limited. 
Furthermore, the effect of corneal thickness on endothelial 
and ocular damage remains a safety concern. Future studies 
are needed to explore these long-term effects as well as other 
aspects of ocular safety.Clinical Ophthalmology 2008:2(4) 867
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